Evotec Starts Phase II Clinical Studies in Treatment-Resistant Depression
The proof-of-concept Phase II study with EVT 101, which is being conducted in the United States, has the main objective of studying the safety and tolerability of EVT 101 while also exploring the efficacy of this intervention. Approximately 100 patients suffering from treatment-resistant depression will participate in it. Treatment-resistance of patients will be confirmed in a 6-week prospective antidepressant treatment phase preceding the actual 4-week double-blind treatment.
Treatment-resistance to antidepressant drugs is observed in up to 30% of depressed patients. NMDA receptor antagonists represent an alternative mechanism that has the potential to improve depression in patients resistant to conventional antidepressants.
Dr Werner Lanthaler, Chief Executive Officer of Evotec AG, commented: "The clinical development of EVT 101 is addressing an area of significant unmet medical need, and this development represents a big market opportunity. We are happy to have Roche, as a recognised pioneer for novel solutions in the CNS area, for this development with us."
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.